Profile data is unavailable for this security.
About the company
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing first-in-class medicines that address rare and difficult to treat diseases. Its flagship commercial product is FIRDAPSE (amifampridine) tablets 10 milligrams (mg), approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) for adults and for children ages six to seventeen. The Company is also marketing FYCOMPA (perampanel) CIII as a prescription medication used alone or with other medicines to treat focal onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. Its portfolio also includes AGAMREE (vamorolone) an oral suspension 40 mg/ml for the treatment of Duchenne Muscular Dystrophy (DMD). The vamorolone is a corticosteroid treatment for patients suffering from DMD.
- Revenue in USD (TTM)411.35m
- Net income in USD65.12m
- Incorporated2006
- Employees167.00
- LocationCatalyst Pharmaceuticals Inc355 ALHAMBRA CIRCLE, SUITE 801CORAL GABLES 33134United StatesUSA
- Phone+1 (305) 529-2522
- Fax+1 (302) 636-5454
- Websitehttps://catalystpharma.com/
Mergers & acquisitions
| Acquired company | CPRX:NAQ since announced | Transaction value |
|---|---|---|
| Santhera Pharmaceuticals Holding-Vamorolone Drug | 36.56% | 231.00m |
